PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34300310-4 2021 The primary endpoint was the effect of dexmedetomidine on the interleukin-6 (IL-6) level measured at pre-operation (Pre-OP), before HIPEC initiation (Pre-HIPEC), immediately after HIPEC; after the end of the operation; and on postoperative day (POD) 1. Dexmedetomidine 39-54 interleukin 6 Homo sapiens 62-75 11575340-10 2001 Interleukin 6 decreased in the dexmedetomidine group. Dexmedetomidine 31-46 interleukin 6 Homo sapiens 0-13 34342722-8 2022 The application of dexmedetomidine in cardiac surgery with CPB can reduce CK-MB and cTn-I concentration and interleukin-6, tumor necrosis factor-alpha levels to a certain extent and shorten the length of Intensive Care Unit stay, but it has no significant effect on IL-10 level, C reactive protein level, the time on ventilator and length of hospital stay. Dexmedetomidine 19-34 interleukin 6 Homo sapiens 108-121 34914243-0 2021 (Effects of low-dose dexmedetomidine combined with hydromorphone in postoperative analgesia and on the serum IL-6 and CRP levels of prostate cancer patients). Dexmedetomidine 21-36 interleukin 6 Homo sapiens 109-113 34914243-1 2021 Objective: To explore the effects of low-dose dexmedetomidine (DM) combined with hydromorphone (HM) in postoperative analgesia and on levels of serum interleukin-6 (IL-6) and C-reactive protein (CRP) in PCa patients. Dexmedetomidine 46-61 interleukin 6 Homo sapiens 150-163 34300310-4 2021 The primary endpoint was the effect of dexmedetomidine on the interleukin-6 (IL-6) level measured at pre-operation (Pre-OP), before HIPEC initiation (Pre-HIPEC), immediately after HIPEC; after the end of the operation; and on postoperative day (POD) 1. Dexmedetomidine 39-54 interleukin 6 Homo sapiens 77-81 33963722-7 2021 On D2, TNF-alpha, L-1beta and IL-6 recovered their baseline levels in medium- and high-dose DEX groups (P > 0.05) but remained elevated in the other two groups. Dexmedetomidine 92-95 interleukin 6 Homo sapiens 30-34 31773201-13 2020 In addition, ISB with DEX showed lower mean plasma IL-6 and IL-8 levels than ISB alone within 48 h postoperatively, with delayed rebound pain. Dexmedetomidine 22-25 interleukin 6 Homo sapiens 51-55 33641076-4 2021 In vivo, Dex markedly reduced pulmonary edema induced by LPS through promoting AFC, prevented LPS-induced downregulation of alpha-, beta-, and gamma-ENaC expression, attenuated inflammatory cell infiltration in lung tissue, reduced the concentrations of TNF-alpha, IL-1beta, and IL-6, and increased concentrations of IL-10 in bronchoalveolar lavage fluid (BALF). Dexmedetomidine 9-12 interleukin 6 Homo sapiens 279-283 33262576-10 2020 DEX alleviated the alveolar capillary epithelial structure damage, increased protein expression of ZO-1 and occludin, inhibited elevation of the expression of TNF-alpha and IL-6 in lung tissue and plasma, and increased protein expression of p-PI3K, p-AKT and HIF-1alpha. Dexmedetomidine 0-3 interleukin 6 Homo sapiens 173-177 32394288-7 2020 We found dexmedetomidine reduced LPS-induced IL-6 and TNF-alpha production and increase Arg1 in primary microglia. Dexmedetomidine 9-24 interleukin 6 Homo sapiens 45-49 32963704-12 2020 However, the inflammatory cytokines IL-6, TNF-alpha, and ICAM-1 in the DEX group were lower than those in the Con group after surgery (T2 to T4; P < 0.05). Dexmedetomidine 71-74 interleukin 6 Homo sapiens 36-40 32851338-11 2020 However, the increases of NF-kappaB, TNF-alpha, IL-6, S-100beta and NSE levels were significantly smaller in the dexmedetomidine groups than those in the control group (P < 0.017). Dexmedetomidine 113-128 interleukin 6 Homo sapiens 48-52 32525823-9 2020 The increased activities of TNFalpha, IL-1beta and IL-6 induced by CSE were partially attenuated by Dex. Dexmedetomidine 100-103 interleukin 6 Homo sapiens 51-55 32343308-6 2020 The simultaneous administration of DEX and sufentanil significantly reduced plasma IL-6 and TNF-alpha concentrations and increased IL-10 level (P < 0.0001, P = 0.0003, and P = 0.0345, respectively), accompanied by better postoperative delirium categories and health statuses of patients (P = 0.024 and P < 0.05, respectively). Dexmedetomidine 35-38 interleukin 6 Homo sapiens 83-87 32477139-12 2020 Conclusion: Dexmedetomidine reduced the incidence of POD in elderly patients on the first day after hip fracture surgery, and reduced IL-6 and TNF-alpha levels over the first 3 days after surgery. Dexmedetomidine 12-27 interleukin 6 Homo sapiens 134-138 31829277-15 2019 In human studies, dexmedetomidine reduced CRP (4 studies), TNFalpha (5 studies), IL-6 (6 studies), IL-1beta (3 studies), and altered several other mediators. Dexmedetomidine 18-33 interleukin 6 Homo sapiens 81-85 32163856-7 2020 In human rheumatoid arthritis fibroblast-like synoviocytes (RA-FLSs), DEX (250 nM and 500 nM) was found to inhibit the expression of IL-1beta, IL-6, MMP-3, MMP-9, and P-P65 following stimulation with TNF-alpha. Dexmedetomidine 70-73 interleukin 6 Homo sapiens 143-147 32076394-0 2020 Dexmedetomidine May Reduce IL-6 Level and the Risk of Postoperative Cognitive Dysfunction in Patients After Surgery: A Meta-Analysis. Dexmedetomidine 0-15 interleukin 6 Homo sapiens 27-31 31604428-7 2019 Dexmedetomidine added to ropivacaine for transversus abdominis plane block significantly reduced serum levels of cortisol, norepinephrine, epinephrine, interleukin-6, blood glucose, mean arterial pressure and heart rate in a dose-dependent manner (P < 0.05), accompanied with decreased anesthetic and opioid consumption during the operation (P < 0.05), but the high dose of dexmedetomidine induced higher incidences of bradycardia than low or medium dose of dexmedetomidine (P < 0.05). Dexmedetomidine 0-15 interleukin 6 Homo sapiens 152-165 31668347-5 2019 DEX infusion during the perioperative period inhibited release of epinephrine, norepinephrine, and cortisol; decreased blood glucose, interleukin (IL)-6, tumour necrosis factor-alpha, and C-reactive protein; and increased interleukin-10 in surgical patients. Dexmedetomidine 0-3 interleukin 6 Homo sapiens 134-152 31356535-12 2019 The IL-6 and IL-8 concentrations in the DEX group were dramatically increased at 6 hours after CPB (P < 0.05). Dexmedetomidine 40-43 interleukin 6 Homo sapiens 4-8 31957703-8 2019 Dex reduced TNF-alpha, IL-6, IL-1beta, ROS, and MDA production, whereas it increased that of SOD and GSH-Px in OGD/R-treated WRL-68 cells. Dexmedetomidine 0-3 interleukin 6 Homo sapiens 23-27 31957703-10 2019 Knockdown of Nrf2 reversed the Dex effects on cell proliferation, apoptosis, and expression of TNF-alpha, IL-6, IL-1beta, ROS, MDA, SOD, and GSH-Px. Dexmedetomidine 31-34 interleukin 6 Homo sapiens 106-110 31402961-12 2019 Dexmedetomidine can significantly improve postoperative cognitive dysfunction in elderly patients with colorectal cancer, and the occurrence of cognitive dysfunction can be affected by age, duration of anesthesia, intraoperative blood loss and the high expression of IL-6 and S-100beta. Dexmedetomidine 0-15 interleukin 6 Homo sapiens 267-271 31186772-0 2019 Effect of dexmedetomidine anesthesia on perioperative levels of TNF-alpha and IL-6 in patients with ovarian cancer. Dexmedetomidine 10-25 interleukin 6 Homo sapiens 78-82 31186772-1 2019 Effect of continuous use of dexmedetomidine during general anesthesia on perioperative levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in patients undergoing radical resection of ovarian cancer was investigated. Dexmedetomidine 28-43 interleukin 6 Homo sapiens 141-154 31186772-8 2019 Serum TNF-alpha and IL-6 levels were significantly lower in the dexmedetomidine group than that in the midazolam group. Dexmedetomidine 64-79 interleukin 6 Homo sapiens 20-24 31186772-9 2019 If dexmedetomidine were continuously used during general anesthesia, the perioperative serum levels of TNF-alpha and IL-6 could be effectively reduced in patients undergoing radical resection of ovarian cancer, and the perioperative stress response was suppressed. Dexmedetomidine 3-18 interleukin 6 Homo sapiens 117-121 31045788-10 2019 Furthermore, perioperative dexmedetomidine treatment significantly decreased IL-6 (SMD = -1.31, 95% CI -1.87-0.75, P < .001) and TNF-alpha (SMD = -2.14, 95% CI -3.14-1.14, P < .001) compared to saline/comparators treatment. Dexmedetomidine 27-42 interleukin 6 Homo sapiens 77-81 30207136-10 2019 At 90 min, IL-6 was significantly lower in the dexmedetomidine group than in the control group (P=0.049). Dexmedetomidine 47-62 interleukin 6 Homo sapiens 11-15 29896269-12 2018 In addition, IL-1and TNF-alpha were downregulated, while IL-6 and SOD were upregulated in patients with cognitive dysfunction after treatment with DEX compared with those in the placebo group. Dexmedetomidine 147-150 interleukin 6 Homo sapiens 57-61 30391912-10 2018 These results might be attributed to inhibition of inflammatory responses and the resulting lower serum levels of IL-6 and TNF-alpha, caused by Dex administration. Dexmedetomidine 144-147 interleukin 6 Homo sapiens 114-118 29549829-6 2018 IL-6 levels in group D2 were significantly lower only at 1 h after surgery than in group S. However, IL-6 levels in delirious patients in group D2 were significantly lower at 1 h and 24 h after surgery than those in group S. Cortisol levels 1 h after surgery were significantly lower in groups D1 and D2 than in group S. CONCLUSIONS: The dose and timing of dexmedetomidine appeared to be important in preventing delirium. Dexmedetomidine 357-372 interleukin 6 Homo sapiens 101-105 29549829-7 2018 The reduced incidence and duration of delirium by dexmedetomidine was associated with reduced levels of IL-6 24 h after surgery. Dexmedetomidine 50-65 interleukin 6 Homo sapiens 104-108 29853785-8 2018 In addition, plasma interleukin-6 was higher in the saline group than in the dexmedetomidine group at postoperative day 1 [118.8 (68.8) versus 78.5 (58.8) pg.ml-1, p = 0.0271]. Dexmedetomidine 77-92 interleukin 6 Homo sapiens 20-33 28668524-8 2017 Serum IL-6 and TNF-alpha level in Dex group was significantly increased at T3 and T4 (P<0.05), and IL-6 and TNF-alpha level in control group was significantly increased at T2, T3, T4 and T5 (P<0.05) when compared with their respective preoperative levels (T1). Dexmedetomidine 34-37 interleukin 6 Homo sapiens 6-10 30589029-3 2018 We hypothesized that DEX could reduce the incidence of POCD caused by sevoflurane anesthesia through decreasing plasma interleukin (IL-6) and tumor necrosis factor (TNF)-alpha concentrations. Dexmedetomidine 21-24 interleukin 6 Homo sapiens 132-136 30589029-10 2018 Conclusion: The POCD incidence was higher in elderly patients receiving sevoflurane anesthesia and DEX could alleviate POCD in these patients through decreasing plasma TNF-alpha and IL-6 concentrations. Dexmedetomidine 99-102 interleukin 6 Homo sapiens 182-186 28668524-9 2017 IL-6 and TNF-alpha levels at T2, T3, T4 and T5 in Dex group were significantly lower than those in control group (P<0.05). Dexmedetomidine 50-53 interleukin 6 Homo sapiens 0-4 26909786-10 2016 DEX as an adjuvant in anesthesia reduced circulating IL-1, IL-6, TNF-alpha, and INF-gamma levels after mini-CPB. Dexmedetomidine 0-3 interleukin 6 Homo sapiens 59-63 28969013-9 2017 Postoperative plasma IL-6 and cortisol levels were lower in dexmedetomidine(3 mug and 5 mug) co-administration groups. Dexmedetomidine 60-75 interleukin 6 Homo sapiens 21-25 27236883-12 2016 CONCLUSION: Dexmedetomidine combied electrical stimulation could effectively prevent the occurrence of postoperative cognition, and reduce levels of NSA, S-100beta, IL-1beta, IL-6 and TNF-alpha. Dexmedetomidine 12-27 interleukin 6 Homo sapiens 175-179 29889401-3 2016 RESULTS: Based on the analysis of hemodynamic parameters, evaluation of pain using a numeric rating scale pain concluded that selective agonist of o-2 adrenergic dexmedetomidine in combination with nefopam provides effective postoperative pain relief in patients who underwent bariatric surgery, and is not a factor for suppression of postoperative inflammatory response Unlike the effects of ketorolac tromethamine, do not always provide a sufficient level of analgesia and reduce the rate of growth in the level of IL-6. Dexmedetomidine 162-177 interleukin 6 Homo sapiens 517-521 26330753-5 2015 This study was carried out to assess how dexmedetomidine modulates histamine-induced Ca(2+) signaling and regulates the expression of pro-inflammatory cytokine genes encoding interleukin (IL)-6 and -8. Dexmedetomidine 41-56 interleukin 6 Homo sapiens 175-200 26885050-6 2015 In this study, we showed Dex inhibited the increase in cTnI and CK-MB, attenuated the production of pro-inflammatory cytokines TNF-alpha, IL-6 and IL-8, and promoted anti-inflammatory cytokine IL-10 production. Dexmedetomidine 25-28 interleukin 6 Homo sapiens 138-142 26899608-4 2016 Serum interleukin-6 (IL-6) levels were significantly lower in the bilateral-DEX group than in the uni-saline group 6 and 24h postoperatively, and were negatively correlated with total DEX dosage 24h postoperatively. Dexmedetomidine 76-79 interleukin 6 Homo sapiens 6-19 26899608-4 2016 Serum interleukin-6 (IL-6) levels were significantly lower in the bilateral-DEX group than in the uni-saline group 6 and 24h postoperatively, and were negatively correlated with total DEX dosage 24h postoperatively. Dexmedetomidine 76-79 interleukin 6 Homo sapiens 21-25 26899608-4 2016 Serum interleukin-6 (IL-6) levels were significantly lower in the bilateral-DEX group than in the uni-saline group 6 and 24h postoperatively, and were negatively correlated with total DEX dosage 24h postoperatively. Dexmedetomidine 184-187 interleukin 6 Homo sapiens 6-19 26899608-4 2016 Serum interleukin-6 (IL-6) levels were significantly lower in the bilateral-DEX group than in the uni-saline group 6 and 24h postoperatively, and were negatively correlated with total DEX dosage 24h postoperatively. Dexmedetomidine 184-187 interleukin 6 Homo sapiens 21-25 26899608-7 2016 The results indicate that perioperative intravenous DEX administration decreases postoperative serum IL-6 levels in patients undergoing bilateral TKA, and has a postoperative analgesic effect in patients undergoing unilateral or bilateral TKA. Dexmedetomidine 52-55 interleukin 6 Homo sapiens 101-105 26330753-10 2015 Collectively, these findings suggest that dexmedetomidine modulates histamine-induced Ca(2+) signaling and IL-6 expression and will be useful for understanding the antagonistic properties of dexmedetomidine on histamine-induced signaling beyond its sedative effect. Dexmedetomidine 42-57 interleukin 6 Homo sapiens 107-111 26330753-10 2015 Collectively, these findings suggest that dexmedetomidine modulates histamine-induced Ca(2+) signaling and IL-6 expression and will be useful for understanding the antagonistic properties of dexmedetomidine on histamine-induced signaling beyond its sedative effect. Dexmedetomidine 191-206 interleukin 6 Homo sapiens 107-111 26196332-7 2015 In conclusion, perioperative adjunctive use of dexmedetomidine substantially decreases serum IL-6, IL-8 and TNF-alpha levels. Dexmedetomidine 47-62 interleukin 6 Homo sapiens 93-97 26379954-8 2015 One- and five-day after operation, the levels of TNF-alpha, NSE and IL-6 in the dexmedetomidine group were significantly lower than those in the control group (P<0.05), and serum SOD significantly increased in the former (P<0.05). Dexmedetomidine 80-95 interleukin 6 Homo sapiens 68-72 24429914-0 2014 Dexmedetomidine inhibits tumor necrosis factor-alpha and interleukin 6 in lipopolysaccharide-stimulated astrocytes by suppression of c-Jun N-terminal kinases. Dexmedetomidine 0-15 interleukin 6 Homo sapiens 57-70 26064392-8 2015 Compared to control group, Dexmedetomidine significantly inhibited the increase of post-operative IL-6 and TNF-alpha levels (P < 0.05). Dexmedetomidine 27-42 interleukin 6 Homo sapiens 98-102 25622744-15 2014 CONCLUSION: Dexmedetomidine preconditioning attenuate remote lung injury of lower limb ischemia-reperfusion, and the mechanism may be related to down-regulation of monocytes TLR4 expression and degradation of IL-6, IL-8 and TNF-alpha level. Dexmedetomidine 12-27 interleukin 6 Homo sapiens 209-213 25769330-10 2015 The levels of TNF-alpha, NSE, and IL-6 in the dexmedetomidine group were significantly reduced compared with those in the control group (P<0.05). Dexmedetomidine 46-61 interleukin 6 Homo sapiens 34-38 24773263-6 2014 Dexmedetomidine infusion also suppressed the rise in mean (SD) interleukin-6 levels after cardiopulmonary bypass (a rise of 124.5 (72.0) pg ml(-1) vs. 65.3 (30.9) pg ml(-1)). Dexmedetomidine 0-15 interleukin 6 Homo sapiens 63-76 24429914-4 2014 This study was designed to evaluate the effects of DEX on tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6) gene expressions in LPS-challenged astrocytes. Dexmedetomidine 51-54 interleukin 6 Homo sapiens 102-115 24429914-4 2014 This study was designed to evaluate the effects of DEX on tumor necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6) gene expressions in LPS-challenged astrocytes. Dexmedetomidine 51-54 interleukin 6 Homo sapiens 117-121 24429914-7 2014 With real-time PCR assay, we found that LPS significantly increased expressions of TNF-alpha and IL-6 in mRNA level; however, these effects could be attenuated by DEX. Dexmedetomidine 163-166 interleukin 6 Homo sapiens 97-101 24429914-8 2014 Furthermore, JNK pathway might be involved in LPS-induced astrocyte activation because JNK phosphorylation was significantly increased, and the inhibition of this pathway mediated by DEX as well as SP600125 (JNK inhibitor) decreased TNF-alpha and IL-6 expressions. Dexmedetomidine 183-186 interleukin 6 Homo sapiens 247-251 24255662-12 2013 The levels of TNF-alpha, IL-6, TLR4 and MyD88 were decreased in the dexmedetomidine hydrochloride treatment groups compared with those in the sham control and untreated ischemia reperfusion groups. Dexmedetomidine 68-97 interleukin 6 Homo sapiens 25-29